Background Adjuvant capecitabine and oxaliplatin (CAPOX) is a standard treatment for
resected colon cancer; however, in patients with moderate renal impairment, the incidence …

Introduction: Adjuvant chemotherapy improves the prognosis of patients with colorectal
cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin …

Purpose: The aim of this study was to provide insight in the use, intensity and toxicity of
therapy with capecitabine and oxaliplatin (CAPOX) and capecitabine monotherapy …

Background/Aim: Past studies have suggested that adjuvant capecitabine and oxaliplatin
(CAPOX) provides decreased tumor relapse and longer survival in patients with curatively …

Background This study was conducted to analyze the feasibility of adjuvant capecitabine
therapy using a tailored-dose escalation strategy in elderly patients with colon cancer (CC) …

Background Undertreatment has been frequently reported in the elderly cancer patient
population. For this reason, we aimed to characterize adjuvant chemotherapy (AC) use …

PURPOSE A number of studies suggest that older patients may have reduced or no benefit
from the addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III …

Purpose 45% of colon cancer patients are elderly, yet they are often deviated from standard
cancer management. The MOSAIC trial favored FOLFOX over FL with superior oncologic …

The aging tsunami is upon us, and nowhere is this experience more challenging than in
caring for the exploding number of older Americans with cancer. Average life expectancy is …

Background/Aim: Adjuvant capecitabine and oxaliplatin (CAPOX) therapy is standard
strategy for colorectal cancer with risk of recurrence. Early dose reduction (EDR) of CAPOX …